Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gliclazide modified release.

× No keyword cloud information.

19 in total

1. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

Authors: N Frey; C Laveille; M Paraire; M Francillard; N H G Holford; Roeline Jochemsen
Journal: Br J Clin Pharmacol Date: 2003-02 Impact factor: 4.335

2. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes.

Authors: A Jönsson; B Hallengren; T Rydberg; A Melander
Journal: Diabetes Obes Metab Date: 2001-12 Impact factor: 6.577

3. Sulphonylureas (specifically glibenclamide) and their correct dosage.

Authors: L Jackson; L Robertson
Journal: S Afr Med J Date: 1989-09-16

4. Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay.

Authors: A Matsuda; T Kuzuya; Y Sugita; K Kawashima
Journal: Horm Metab Res Date: 1983-09 Impact factor: 2.936

Review 5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Authors: Andrew J Krentz; Clifford J Bailey
Journal: Drugs Date: 2005 Impact factor: 9.546

6. Impaired effect of sulfonylurea following increased dosage.

Authors: E Wåhlin-Boll; G Sartor; A Melander; B Scherstén
Journal: Eur J Clin Pharmacol Date: 1982 Impact factor: 2.953

Review 7. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.

Authors: K J Palmer; R N Brogden
Journal: Drugs Date: 1993-07 Impact factor: 9.546

8. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes.

Authors: P Drouin; E Standl
Journal: Diabetes Obes Metab Date: 2004-11 Impact factor: 6.577

Review 9. Gliclazide modified release.

Authors: Jane K McGavin; Caroline M Perry; Karen L Goa
Journal: Drugs Date: 2002 Impact factor: 9.546

10. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.

Authors: D C Simonson; I A Kourides; M Feinglos; H Shamoon; C T Fischette
Journal: Diabetes Care Date: 1997-04 Impact factor: 19.112

2 in total

1. Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study.

Authors: Poobalan Naidoo; Rambiritch Virendra; Mayet Layla
Journal: Curr Ther Res Clin Exp Date: 2006-03

Review 2. Optimal utilisation of sulphonylureas in resource-constrained settings.

Authors: Poobalan Naidoo; Virendra Rambiritch; Neil Butkow; Selvarajah Saman
Journal: Cardiovasc J Afr Date: 2014 Mar-Apr Impact factor: 1.167

2 in total